Trial Profile

A phase Ib MAD trial of GRI-0803

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 17 May 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs GRI 0803 (Primary)
Indications Systemic lupus erythematosus
Focus Adverse reactions
Sponsors GRI Bio

Most Recent Events

13 May 2024 According to a GRI Bio media release, the company expects to complete IND-enabling studies and File IND and launch Phase 1a/b in Q3 2024
29 May 2023 New trial record
22 May 2023 According to a GRI Bio media release, the company expects to complete IND-enabling studies in Q1 2024 and file an IND in 1H 2024. Topline data from this study expected in Q4 2024.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com